For instance, Family Health Study participants with heart failure and preserved systolic function had a mortality rate of 9% compared to 3% for their age- and gender-matched controls.
The annual mortality rate is intermediate between the prognosis for those without heart failure and for those with heart failure and reduced systolic function. Patients with heart failure and preserved systolic function have a poor prognosis. While this treatment has been shown to be useful in treating heart failure with reduced systolic function, it has not been studied in patients with preserved systolic function. This study is a randomized clinical trial of a novel therapeutic approach, specifically the use of spironolactone, an aldosterone antagonist, in treating these patients. However, there is now an emerging awareness that nearly half of the patients with heart failure have preserved systolic function and that the survival of these patients is adversely affected. Therapeutic trials of heart failure have dealt almost exclusively with patients who have systolic dysfunction. As the United States population ages, heart failure will continue to grow as a public health concern. Indeed, it is the most common discharge diagnosis in patients older than 65 years. Heart failure (HF) is a major cause of morbidity and mortality, particularly in older people. Why Should I Register and Submit Results?.
0 kommentar(er)
